Anticonvulsants and antipsychotics in the treatment of bipolar disorder

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 6, 1998, Pages 74-82

  Keck Jr , Paul E ^a,b   McElroy, Susan L ^a   Strakowski, Stephen M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Biological Psychiatry Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ACUTE DISEASE; BIPOLAR DEPRESSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; REVIEW;

ACETIC ACIDS; AMINES; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CLINICAL TRIALS; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HUMANS; TRIAZINES;

EID: 2642613686     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Goodwin FK, Jamision KR. Manic-depressive illness. New York, NY: Oxford University Press; 1990
2. Keck PE Jr, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol 1996;16(suppl 1):15S-23S
3. Keck PE Jr, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorders. J Neuropsychiatry Clin Neurosci 1992;4:395-405
4. Baldessarini RJ. Chemotherapy in Psychiatry. Cambridge. Mass: Harvard University Press; 1985
5. Hirschfeld RMA, Clayton PJ, Cohen I, et al. Practice guidelines for the treatment of patients with bipolar disorders. Am J Psychiatry 1994;151 (suppl 12):1-31
6. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder. J Clin Psychiatry 1996;57(suppl 12A):11-88
7. Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996;57(suppl 9):49-52
8. McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996;57(suppl 3):14-26
9. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry 1995;56(suppl 3):25-30
10. Keck PE Jr, McElroy SL, Bennett JA. Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatry 1996;57(suppl 13):13-18
11. Bowden CL. Dosing strategies and time course of response to antimanic drugs. J Clin Psychiatry 1996;57(suppl 13):4-9
12. Calabrese JR, Woyshville MJ, McElroy SL, et al. Spectrum of efficacy of lamotrigine in treatment-refractory manic depression. Presented at the 2nd International Conference on New Directions in Affective Disorders; Sept 3-8, 1995; Jerusalem, Israel
13. Keck PE Jr, McElroy SL, Strakowski SM, et al. Pharmacologic treatment of schizoaffective disorder. Psychopharmacol Bull 1994;114:529-538
14. Sernyak MJ, Griffin RA, Johnson RM, et al. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry 1994;151:133-135
15. Keck PE Jr, McElroy SL, Strakowski SM, et al. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996;57:147-151
16. Verdoux H, Gonzales B, Takei N, et al. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. J Affect Disord 1996;38:81-87
17. Zarate CA Jr, Tohen M, Hennen J, et al. Neuroleptic exposure following inpatient treatment of first-episode mania. Presented at the 35th annual meeting of the American College of Neuropsychopharmacology; Dec 8-13, 1996; San Juan. Puerto Rico
18. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
19. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48: 62-68
20. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproic acid and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:247-250
21. Emrich HM, Von Zerssen D, Kissling W. On a possible role of GABA in mania: therapeutic efficacy of sodium valproate. In: Costa E, Dicharia G, Gessa GL, eds. GABA and Benzodiazepine Receptors. New York, NY: Raven Press; 1981:287-296
22. Brennan MJW, Sandyk R, Borsook D. Use of sodium valproate in the management of affective disorders: basic and clinical aspects. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam, The Netherlands: Excerpta Medica; 1994:56-65
23. Post RM, Berretini W, Uhde TW, et al. Selective response to the anticonvulsant carbamazepine in manic depressive illness: a case study. J Clin Psychopharmacol 1984;4:178-185
24. McElroy SL, Keck PE Jr, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-146
25. Bowden CL, Janicak PG, Orsulak P, et al. Relationship of serum valproate concentration to response in mania. Am J Psychiatry 1996;153:765-770
26. Keck PE Jr, McElroy SL, Tugrul KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993;54:305-308
27. McElroy SL, Keck PE Jr, Tugrul KC, et al. Valproate as a loading treatment in acute mania. Neuropsychobiology 1993;27:146-149
28. Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54: 37-42
29. Calabrese JR, Markovitz PJ, Kimmel SE, et al. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12(suppl 1):53S-56S
30. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Treatment of rapid-cycling bipolar disorder with sodium valproate. J Clin Psychopharmacol 1988:8: 275-279
31. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995;56(suppl 3):19-24
32. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Correlates of antimanic response to valproate. Psychopharmacol Bull 1991;27:127-133
33. Calabrese JR, Woyshville MJ, Kimmel SE, et al. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993;13:280-283
34. McElroy SL, Pope HG Jr, Keck PE Jr, et al. Treatment of psychotic disorders with valproate: a series of 73 cases. Psychiatrie Psychobiologie 1988; 3:81-85
35. Lambert P-A. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam, The Netherlands: Excerpta Medica; 1984:33-44
36. Davis LL, Kabel D, Patel D, et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996;32:647-652
37. Lambert P-A, Venaud G. The use of valpromide in psychiatry. Encephale 1987;8:367-373
38. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Clinical and research implications of the diagnosis of mixed mania or hypomania. Am J Psychiatry 1992;149:1633-1644
39. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Communications in Psychopharmacology 1978;2:159-175
40. Okuma T, Inanga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine. Psychopharmacol (Berl) 1979;66: 211-217
41. Grossi E, Sacchetti E, Vita A. Carbamazepine vs chlorpromazine in mania: a double-blind trial. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam. The Netherlands: Excerpta Medica: 1984:177-187
42. Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987;48:89-93
43. Small JG, Klapper MH, Miketein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48:915-921
44. Ketter TA, Post RM. Clinical pharmacology and pharmacokinetics of carbamazepine. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in Mood Disorders. New York, NY: Marcel Dekker; 1994;147-188
45. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of antimanic response to carbamazepine. Psychiatry Res 1987;21:71-83
46. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993;27:138-145
47. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986;143:29-34
48. Small JG. Anticonvulsants in affective disorders. Psychopharmacol Bull 1990;26:25-36
49. Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Arch Gen Psychiatry 1989;46:794-800
50. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine prophylaxis of manic depressive illness. Psychopharmacol (Berl) 1981;73:95-96
51. Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986;47:490-494
52. Watkins SE, Callender K, Thomas DR. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987;150: 180-182
53. Bellaire W, Demish K, Stoll K-D, et al. Carbamazepine versus lithium in prophylaxis of recurrent affective disorder. Psychopharmacol Bull 1988;96 (suppl):287
54. Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine versus lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153: 198-204
55. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85: 114-118
56. Murphy DJ, Gannon MA, McGennis A. Carbamazepine in bipolar affective disorder. Lancet 1989;2:1151-1152
57. Frankenburg FR, Tohen M, Cohen BM, et al. Long-term response to carbamazepine: a retrospective study. J Clin Psychopharmacol 1988;8:130-132
58. Post RM, Leverich GS, Rosuff AS, et al. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990;10:318-327
59. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder [letter]. Am J Psychiatry 1996;153:1236
60. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol [letter]. Am J Psychiatry 1995;152:1399
61. Stanton SP, Keck PE Jr, McElroy SL. Treatment of acute mania with gabapentin [letter]. Am J Psychiatry 1997;154:287
62. Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder. Am J Psychiatry 1997;154:291-292
63. McElroy SL, Soutullo CA, Keck PE Jr, et al. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997; 9:99-103
64. Young LT, Robb J, Patelis-Siotis I, et al. Gabapentin in bipolar depression: a case study. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, 1997; San Diego, Calif. Abstract NR452:190
65. Short C, Cooke L. Hypomania induced by gabapentin. Br J Psychiatry 1995;166:679-680
66. Johnson G, Gershan S, Burdock EI, et al. Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: an interim report. Compr Psychiatry 1968;9:563-573
67. Platman SR. A comparison of lithium carbonate and chlorpromazine in mania. Am J Psychiatry 1970;127:351-353
68. Spring G, Schweid D, Gray C, et al. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. Am J Psychiatry 1970;126:1306-1310
69. Johnson G, Gershan S, Burdock EI, et al. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 1971;119:267-276
70. Prien RF, Caffey EM, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1972;26:146-153
71. Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975;32:34-42
72. Takahashi R, Sakuma A, Itoh K, et al. Comparison of efficacy of lithium carbonate and chlorpromazine in mania: report of collaborative study group on treatment of mania in Japan. Arch Gen Psychiatry 1975;32: 1310-1318
73. Goodwin FK, Zis AP. Lithium in the treatment of mania: comparisons with neuroleptics. Arch Gen Psychiatry 1979;36:840-844
74. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980;2:279-288
75. Post RM, Jimerson DC, Bunney WE Jr, et al. Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacol (Berl) 1980;67:297-305
76. Cookson JC, Silverstone T, Wells B. A double-blind controlled study of pimozide versus chlorpromazine in mania. Psychopharmacol Bull 1980; 16:38-41
77. Janicak PG, Bresnahan DB, Sharma R, et al. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol 1988;8:33-37
78. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-436
79. Schatzberg AF, Rothchild AJ, Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992;149:733-745
80. Hendrick V, Altshuler LL, Szuba MP. Is there a role for neuroleptics in bipolar depression? J Clin Psychiatry 1994;55:533-535
81. White E, Cheung T, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8:119-122
82. Morgan HG. The incidence of depressive symptoms during recovery from hypomania. Br J Psychiatry 1972;120:537-539
83. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 1980;13:156-167
84. Levine S. The management of resistant depression. Acta Psychiatrica Belgica 1986;86:141-151
85. Kane JM, Jeste DV, Barnes TRE, et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992
86. Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986;43:342-346
87. Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988;145:1455-1456
88. Naylor GJ, Scott CR. Depot injections for affective disorders [letter]. Br J Psychiatry 1980;136:105
89. Lowe MR, Batchelor DH. Depot neuropeptics and manic depressive psychosis. Int Clin Psychopharmacol 1986;1(suppl 1):53-62
90. Lowe MR, Batchelor DH. Lithium and neuroleptics in the management of manic depressive psychosis. Human Psychopharmacology 1990;5: 267-274
91. Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994;165:827-829
92. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981;64:226-237
93. Esparon J, Kollaori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-725
94. McElroy SL, Dessain EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-414
95. Zarate CA Jr, Tohen M. Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995;56:411-417
96. Suppes T, McElroy SL, Gilbert J, et al. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-280
97. Calabrese JR, Rimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-764
98. Goodnick PJ. Risperidone treatment of refractory acute mania [letter]. J Clin Psychiatry 1995;56:431-432
99. Tohen M, Zarate CA Jr, Centorrino F, et al. Rispendone in the treatment of mania. J Clin Psychiatry 1996;57:249-253
100. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466-470
101. Ghaemi SN, Sachs GS, Baldassano CF, et al. Management of bipolar disorder with adjunctive risperidone: response to open treatment. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 22, 1995; Miami Fla. Abstract NR 82:77
102. Madhusoodanan S, Brenner R, Aranjo L, et al. Efficacy of rispendone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514-518
103. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429
104. Schaffer CB, Schaffer LC. The use of risperidone in the treatment of bipolar disorder [letter]. J Clin Psychiatry 1996;57:136
105. Tomlinson WG. Rispendone and mania. Am J Psychiatry 1996;153: 132-133
106. Koek RJ, Kessler CC. Probable induction of mania by risperidone [letter]. J Clin Psychiatry 1996;57:174-175
107. O'Croinin F, Zibin T, Holt L. Hypomania associated with rispendone [letter]. Can J Psychiatry 1995;56:51
108. Sajatovic M, DiGiovanni SK, Bastain B, et al. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania. Psychopharmacol Bull 1996;32:55-61
109. Dwight MM, Keck PE Jr, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994;344:554-555
110. Diaz SF. Mania associated with risperidone use [letter]. J Clin Psychiatry 1996;57:41-42
111. Hillert A, Maier W, Wetzet H, et al. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: a functional approach. Pharmacopsychiatry 1992;25:213-217
112. Lu Y, Sanger T, Beasley C, et al. Olanzapine in the treatment of schizoaffective disorder. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; Dec. 11-14, 1995; San Juan, Puerto Rico
113. Keck PE Jr, McElroy SL. Olanzapine: a novel antipsychotic medication. Today's Therapeutic Trends 1996;14:63-78
114. Keck PE Jr, McElroy SL, Strakowski SM. New developments in the pharmacologic treatment of schizoaffective disorder. J Clin Psychiatry 1996;57(suppl 9):41-48